Art

J-GLOBAL ID：201502208914275571   Reference number：15A0954346

Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone

ジプラシドンのコントロール放出処方の可能性を評価する薬物シンチグラフィー研究

Author (6)： THOMBRE Avinash G. (Pfizer Inc., Center for Discovery and Dev. Sciences, Groton, CT 06340, USA) ,  SHAMBLIN Sheri L. (Pfizer Inc., Center for Discovery and Dev. Sciences, Groton, CT 06340, USA) ,  MALHOTRA Bimal K. (Pfizer Inc., Clinical Pharmacology, New York, NY 10017, USA) ,  CONNOR Alyson L. (Quotient Clinical, Nottingham, GBR) ,  WILDING Ian R. (Quotient Clinical, Nottingham, GBR) ,  CALDWELL W. Brett (Bend Res. Inc., Bend, OR 97701, USA)
Material： Journal of Controlled Release  (J Control Release)
Volume： 213  Page： 10-17  Publication year： Sep. 10, 2015 
JST Material Number： C0308D  ISSN： 0168-3659  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Thesaurus term： *psychotropic drug ,...
Semi thesaurus term： *drug controlled release ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=15A0954346&from=J-GLOBAL&jstjournalNo=C0308D") }}

JST classification (3)： Basic biopharmacy  (GY01021U) ,  Basic research of psychotropic drugs  (GW03100Y) ,  Physicochemical characteristics of drugs  (GV01060M)

Substance index (1)： Ziprasidone

Reference (56)：

• N.C. Patel, P.E. Keck Jr., Ziprasidone: efficacy and safety in patients with bipolar disorder, Expert Rev. Neurother. 6 (2006) 1129-1138.
• W.M. Greenberg, L Citrome, Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials, CNS Drug Rev. 13 (2007) 137-177.
• L. Zimbroff Dan, H. Allen Michael, J. Battaglia, L. Citrome, A. Fishkind, A. Francis, L Herr Daniel, D. Hughes, M. Martel, H. Preval, R. Ross, Best clinical practice with ziprasidone IM: update after 2 years of experience, CNS Spectr. 10 (2005) 1-15.
• T.S. Harrison, L.J. Scott, Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder, CNS Drugs 20 (2006) 1027-1052.
• P.D. Harvey, C.R. Bowie, Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness, Expert. Opin. Pharmacother. 6 (2005) 337-346.

Terms in the title (9)： ジプラシドン ,  コントロール ,  放出 ,  処方 ,  可能性 ,  評価 ,  薬物 ,  シンチグラフィー ,  研究